These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15090736

  • 1. Brostallicin: a new concept in minor groove DNA binder development.
    Broggini M, Marchini S, Fontana E, Moneta D, Fowst C, Geroni C.
    Anticancer Drugs; 2004 Jan; 15(1):1-6. PubMed ID: 15090736
    [Abstract] [Full Text] [Related]

  • 2. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M, Broggini M.
    Cancer Res; 2002 Apr 15; 62(8):2332-6. PubMed ID: 11956092
    [Abstract] [Full Text] [Related]

  • 3. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
    Lorusso D, Mainenti S, Pietragalla A, Ferrandina G, Foco G, Masciullo V, Scambia G.
    Expert Opin Investig Drugs; 2009 Dec 15; 18(12):1939-46. PubMed ID: 19938904
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
    Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M.
    Clin Cancer Res; 2003 Nov 01; 9(14):5402-8. PubMed ID: 14614026
    [Abstract] [Full Text] [Related]

  • 5. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I, Baraldi PG, Cozzi P, Caldarelli M, Geroni C, Marchini S, Mongelli N, Romagnoli R.
    J Med Chem; 2004 May 06; 47(10):2611-23. PubMed ID: 15115402
    [Abstract] [Full Text] [Related]

  • 6. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
    Sabatino MA, Geroni C, Ganzinelli M, Ceruti R, Broggini M.
    Epigenetics; 2013 Jun 06; 8(6):656-65. PubMed ID: 23771052
    [Abstract] [Full Text] [Related]

  • 7. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Caponigro F, Lorusso D, Fornari G, Barone C, Merlano M, Airoldi M, Schena M, MacArthur R, Weitman S, Jannuzzo MG, Crippa S, Fiorentini F, Petroccione A, Comis S.
    Cancer Chemother Pharmacol; 2010 Jul 06; 66(2):389-94. PubMed ID: 20480279
    [Abstract] [Full Text] [Related]

  • 8. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
    Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML.
    Clin Cancer Res; 2004 Jan 15; 10(2):468-75. PubMed ID: 14760067
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
    Ten Tije AJ, Verweij J, Sparreboom A, Van Der Gaast A, Fowst C, Fiorentini F, Tursi J, Antonellini A, Mantel M, Hartman CM, Stoter G, Planting AS, De Jonge MJ.
    Clin Cancer Res; 2003 Aug 01; 9(8):2957-64. PubMed ID: 12912942
    [Abstract] [Full Text] [Related]

  • 10. Role of glutathione transferases in the mechanism of brostallicin activation.
    Pezzola S, Antonini G, Geroni C, Beria I, Colombo M, Broggini M, Marchini S, Mongelli N, Leboffe L, MacArthur R, Mozzi AF, Federici G, Caccuri AM.
    Biochemistry; 2010 Jan 12; 49(1):226-35. PubMed ID: 19950984
    [Abstract] [Full Text] [Related]

  • 11. Development of distamycin-related DNA binding anticancer drugs.
    Marchini S, Broggini M, Sessa C, D'Incalci M.
    Expert Opin Investig Drugs; 2001 Sep 12; 10(9):1703-14. PubMed ID: 11772279
    [Abstract] [Full Text] [Related]

  • 12. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.
    Guirouilh-Barbat J, Zhang YW, Pommier Y.
    Mol Cancer Ther; 2009 Jul 12; 8(7):1985-94. PubMed ID: 19584235
    [Abstract] [Full Text] [Related]

  • 13. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
    Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P.
    Eur J Cancer; 2014 Jan 12; 50(2):388-96. PubMed ID: 24215845
    [Abstract] [Full Text] [Related]

  • 14. The discovery of a new potential anticancer drug: a case history.
    Cozzi P.
    Farmaco; 2003 Mar 12; 58(3):213-20. PubMed ID: 12620417
    [Abstract] [Full Text] [Related]

  • 15. A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.
    Cozzi P.
    Farmaco; 2001 Mar 12; 56(1-2):57-65. PubMed ID: 11347968
    [Abstract] [Full Text] [Related]

  • 16. Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.
    Marchini S, Cirò M, Gallinari F, Geroni C, Cozzi P, D'Incalci M, Broggini M.
    Br J Cancer; 1999 Jun 12; 80(7):991-7. PubMed ID: 10362106
    [Abstract] [Full Text] [Related]

  • 17. Modulation of antitumor alkylating agents (AA).
    Teicher BA, Frei E.
    Cancer Treat Res; 1991 Jun 12; 57():261-95. PubMed ID: 1686721
    [No Abstract] [Full Text] [Related]

  • 18. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
    Townsend DM, Findlay VL, Tew KD.
    Methods Enzymol; 2005 Jun 12; 401():287-307. PubMed ID: 16399394
    [Abstract] [Full Text] [Related]

  • 19. The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
    Coley HM, Mongelli N, D'Incalci M.
    Biochem Pharmacol; 1993 Feb 09; 45(3):619-26. PubMed ID: 8442762
    [Abstract] [Full Text] [Related]

  • 20. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC, Fowst C, de Balincourt C, di Paola ED, van Glabbeke M, Judson I, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Eur J Cancer; 2007 Jan 09; 43(2):308-15. PubMed ID: 17095209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.